Skip to main content
Equibles
ADCT logo

ADCT · ADC Therapeutics SA

Track ADCT — free

Use ADCT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ADCT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.96 -0.08 (-7.68%) At close · Aug 20
Market Cap
$122.57M
Shares
127.67M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.96 Open$1.02 Day$0.95–1.04 52W close$0.96–4.88 Avg vol 30d1.2M Short int5.1M · 4.0% float · 6.1d Short vol49% Last earningsAug 13, 2026 DataMay 2020–Aug 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Nov 13, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −69%
      below
      Price vs 50-day avg −16%
      below
      RSI (14) 36
      neutral
      MACD trend Positive
      52-week position 0%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −21%
      trailing
      6-month return −77%
      trailing
      YTD return −73%
      this year
      Relative strength −88%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $3 — 200d above 50d
      Institutional flow Distributing
      -4% holders QoQ · +27 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.99% of float · ▼ -8.0% MoM · 6.1 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      113 holders — mid 3-yr range
      Squeeze score 61
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +15%
      Y/Y
      EPS growth +31%
      Y/Y
      Free cash flow $-141.4M
      Balance sheet $258.3M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 92%
      annualized · 1-yr
      Max drawdown −80%
      past year
      ATR 10.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 13, 2026
      Annualized estimated cost savings · from the reorganization $10M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 3 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −69% Bearish
      Price vs 50-day avg
      −16% Bearish
      RSI (14)
      36 Neutral
      MACD trend
      Positive Bullish
      52-week position
      0% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $3 — 200d above 50d
      Institutional flow Distributing
      -4% holders QoQ · +27 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.99% of float · ▼ -8.0% MoM · 6.1 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      113 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $1 Now $1 · 0% Range high $5
      vs 200-day avg -69% vs 50-day avg -16%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Best overall response rate (ORR) 89.8% LOTIS-7 Phase 1b data reported December 2025 —
      Cash and cash equivalents $261M As of December 31, 2025 —
      Complete response rate 77.6% LOTIS-7 Phase 1b data reported December 2025 —
      ZYNLONTA net product revenue $73M Full year 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ADCT
      ADC Therapeutics SA
      this stock
      		$122.57M -72.8% +14.9% — 4.0%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $57.85B +16.3% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $50.24B +1.7% — — 0.0%
      HLN
      Haleon plc
      		 $43.41B -2.4% — — 0.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      113
      % held
      63.4%
      Net QoQ
      -2.8M sh
      Top holder
      Nantahala Capital Managem…
      Held Float
      View
      Held by Funds
      Fund positions
      25
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      5.1M
      Days to cover
      6.1d
      Change
      -442.0K sh
      View
      Short Volume
      Short vol %
      49%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      192.5K
      Value
      $213.7K
      As of
      Jul 29, 2026
      View
      Off-Exchange
      Off-exchange %
      36.9%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $81.4M
      Net income (FY)
      $-142.6M
      EPS diluted
      $-1.12
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 13, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $20.2K
      Shares
      7.0K
      Filed
      Jun 18, 2024
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ADCT -8.6% -21.3% -76.6% -8.6% -72.8%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY -6.6% -24.6% -87.8% -10.6% -84.6%
      Key facts CIK 1771910 CUSIP H0036K147 13F (30d) 109 filings 106 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)